Ustekinumab
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Ustekinumab: From Psoriasis to Atopic Dermatitis
One-Sentence Summary
Ustekinumab is a human monoclonal antibody targeting IL-12/IL-23, established for chronic inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The TxGNN model predicts it may be effective for dermatitis (specifically atopic dermatitis), with 7 clinical trials and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis (per literature evidence; no structured EU regulatory record in this pack) |
| Predicted New Indication | Dermatitis (atopic dermatitis) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| EU Market Status | Not Marketed (per this dataset) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the structured record. Based on known information from the supporting literature, Ustekinumab is a human IgG1 monoclonal antibody that binds the shared p40 subunit of interleukin-12 and interleukin-23, thereby suppressing Th1, Th17, and Th22 pathway activation. It is a well-established biologic for moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
Atopic dermatitis and psoriasis are both chronic, immune-mediated inflammatory skin diseases with overlapping — though not identical — cytokine pathways. While psoriasis is classically Th17/Th22-dominant, atopic dermatitis has traditionally been considered a Th2-dominant disease; however, more recent immunophenotyping shows meaningful Th17/Th22 activation in atopic dermatitis skin as well, which provides a biological rationale for IL-12/23 blockade.
This mechanistic overlap is directly reflected in the clinical evidence base: two completed Phase 2 randomized, double-blind, placebo-controlled trials (including a dedicated Japanese severe atopic dermatitis study) evaluated ustekinumab specifically in atopic dermatitis, and multiple systematic reviews/meta-analyses have since synthesized biologic therapy data — including ustekinumab — in this population. This combination of mechanistic plausibility and early-phase clinical testing is why the TxGNN prediction is considered reasonable rather than speculative.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01945086 | Phase 2 | Completed | 79 | Randomized, double-blind, placebo-controlled trial of two ustekinumab doses vs. placebo in adult Japanese patients with severe atopic dermatitis |
| NCT01806662 | Phase 2 | Completed | 32 | Randomized pilot study of ustekinumab in chronic atopic dermatitis patients with sub-optimal response to prior therapy |
| NCT05535738 | Phase 2/3 | Recruiting | 45 | Suction-blistering contact dermatitis model using biologic medications to study skin inflammation mechanisms |
| NCT07352566 | Phase 4 | Not yet recruiting | 10 | Microdevice delivering FDA-approved atopic dermatitis/psoriasis drugs directly into skin at sub-systemic doses |
| NCT02074982 | Phase 3 | Completed | 676 | CLEAR study: secukinumab vs. ustekinumab in moderate-to-severe plaque psoriasis (original indication, comparator arm) |
| NCT07041112 | N/A (Observational) | Completed | 1000 | Retrospective cohort on genetic/cardiometabolic factors affecting 10-year biologic drug survival in psoriasis/psoriatic arthritis |
| NCT01356758 | N/A (Observational) | Completed | 126 | Cardiovascular risk assessment in severe psoriasis patients treated with biologic agents |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27304428 | 2017 | RCT (Phase II) | Experimental Dermatology | Ustekinumab assessed vs. placebo in 33 moderate-to-severe AD patients; IL-12/23p40 blockade rationale via Th1/Th17/Th22 suppression |
| 28338223 | 2017 | RCT (Phase II) | British Journal of Dermatology | Randomized, double-blind, placebo-controlled trial in Japanese patients with severe atopic dermatitis |
| 33074565 | 2021 | Systematic Review/Meta-analysis | Allergy | EAACI evidence base review of systemic treatments (including ustekinumab) for moderate-to-severe AD |
| 29164954 | 2018 | Systematic Review | J Dermatolog Treat | Systematic review of ustekinumab efficacy and safety specifically in atopic dermatitis |
| 29098604 | 2018 | Systematic Review/Meta-analysis | Am J Clin Dermatol | Meta-analysis of biologics (incl. ustekinumab) efficacy in atopic dermatitis |
| 33849369 | 2022 | Real-World Evidence | J Dermatolog Treat | Real-world analysis of ustekinumab effectiveness in AD patients |
| 36208443 | 2022 | Review | Dermatologic Therapy | Review of off-label uses of ustekinumab across dermatologic conditions |
| 31514420 | 2019 | Review | Children (Basel) | Biologic treatment options review for pediatric psoriasis and atopic dermatitis |
| 33282108 | 2020 | Review | J Clin Aesthet Dermatol | Updated review of biologic treatment options for pediatric psoriasis and AD |
| 39201826 | 2024 | Narrative Review | Children (Basel) | Review of biologics/small molecules for pediatric AA, psoriasis, AD, and HS |
EU Market Information
No EU marketing authorization records are currently on file for Ustekinumab in this dataset (total_licenses = 0). This should be cross-checked directly against EMA/national registers, as the absence of records here reflects a data gap rather than a confirmed regulatory status.
Safety Considerations
Please refer to the SmPC for safety information. Key warnings, contraindications, and drug-drug interaction data are not currently available in this Evidence Pack (flagged as a Blocking data gap — TFDA/EU label warnings and contraindications must be sourced before any safety-stage evaluation).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two completed Phase 2 randomized, double-blind, placebo-controlled trials plus multiple systematic reviews and a real-world evidence study provide L2-level clinical support for ustekinumab in atopic dermatitis, and the IL-12/23 mechanism has reasonable biological plausibility. However, a Blocking-severity data gap in safety labeling (contraindications, key warnings, DDI) and the absence of confirmed EU marketing authorization data in this pack mean the candidate cannot yet advance to a full safety assessment (S1) without further data.
To proceed, the following is needed:
- TFDA/EU SmPC warnings and contraindications (Blocking gap — required before S1 safety review)
- Confirmed original mechanism of action (MOA) documentation from DrugBank
- Verification of actual EU marketing authorization status, since Ustekinumab is a known marketed biologic and the “Not Marketed / 0 licenses” result likely reflects incomplete data ingestion rather than true absence from the EU market
- Monitoring of ongoing/upcoming trials (NCT05535738, NCT07352566) for maturing Phase 2/3 and Phase 4 evidence in atopic dermatitis
Note on other TxGNN-predicted candidates (ranks 2–10): neonatal dermatomyositis, acne keloid, acrodermatitis chronica atrophicans, amyopathic dermatomyositis, childhood interstitial lung disease with connective tissue disease, familial hydroa vacciniforme, severe nonproliferative diabetic retinopathy, pityriasis lichenoides, and acute lichenoid pityriasis were all evaluated at L5 (model prediction only, no clinical trials or literature) and are recommended Hold. Several (e.g., acrodermatitis chronica atrophicans, diabetic retinopathy) show mechanistically implausible or potentially contrary rationale and are suspected knowledge-graph false positives; these should not be prioritized for further evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.